A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

Breast Cancer Research and Treatment

Volumn 123, Issue 2, 2010, Pages 471-475

  Yardley, Denise ^a,b   Burris III, Howard ^a,b   Peacock, Nancy ^b   Raefsky, Eric ^b   Melnik, Marianne ^c   Inhorn, Roger ^d   Shipley, Dianna ^b   Hainsworth, John ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM   (United States)

^d Mercy Hospital Portland Maine   (United States)

Author keywords

Adjuvant; Cyclophosphamide; Early stage breast cancer; HER2 positive; Nab paclitaxel; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; NANOPARTICLE ALBUMIN BOUND PACLITAXEL; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EARLY CANCER; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ALBUMINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NANOPARTICLES; NEOPLASM STAGING; PACLITAXEL; PILOT PROJECTS; RECEPTOR, ERBB-2; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77956189183     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1047-0     Document Type: Article

References (13)

1. MJ Piccart-Gebhart M Procter B Leyland-Jones, et al.. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L 16236737
2. N Desai V Trieu R Yao, et al.. 2004 Increased endothelial transcytosis of nanoparticle albumin-bound paclitaxel (ABI-2007) by gp60-receptors: a pathway inhibited by Taxol Breast Cancer Res Treat 88 1071
3. WJ Gradishar D Krasnojon S Cheporov, et al.. 2009 Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer J Clin Oncol 27 3611 3619 10.1200/JCO.2008.18.5397 1:CAS:528:DC%2BD1MXhtVOnu7nE 19470941
4. WJ Gradishar S Tjulandin N Davidson, et al.. 2005 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 7794 7803 10.1200/JCO.2005.04.937 1:CAS:528:DC%2BD2MXht1Cqs7nK 16172456
5. S Jones FA Holmes J O'Shaughnessy, et al.. 2009 Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735 J Clin Oncol 27 1177 1183 10.1200/JCO.2008.18.4028 1:CAS:528: DC%2BD1MXktFKhs7c%3D 19204201
6. SE Jones MA Savin FA Holmes, et al.. 2006 Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer J Clin Oncol 24 5381 5387 10.1200/JCO.2006.06.5391 1:CAS:528:DC%2BD2sXisVSjtQ%3D%3D 17135639
7. Slamon D, Eiermann W, Robert N et al.. (2008) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients
8. MC Green AU Buzdar T Smith, et al.. 2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 5983 5992 10.1200/JCO.2005.06.232 1:CAS:528:DC%2BD2MXhtVKgtb3O 16087943
9. AD Seidman D Berry C Cirrincione, et al.. 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 1642 1649 10.1200/JCO.2007.11. 6699 1:CAS:528:DC%2BD1cXltlWhsr0%3D 18375893
10. JA Sparano M Wang S Martino, et al.. 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663 1671 10.1056/NEJMoa0707056 1:CAS:528:DC%2BD1cXkslCitLk%3D 18420499
11. E Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
12. H Joensuu P-L Kellokumpu-Lehtinen P Bono, et al.. 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809 820 10.1056/NEJMoa053028 1:CAS:528:DC%2BD28Xhsl2gsrY%3D 16495393
13. EH Romond EA Perez J Bryant, et al.. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F 16236738